Looking at the patent landscape of antibiotics to identify global leaders

As the global research community is scrambling to develop solutions and help the world recover from the impact of Covid-19, we should not stay blind to other medical risks on the horizon which should be addressed. Chief among these is drug resistant bacteria, a risk which could potentially lead to almost an equal impact as by the current pandemic.

Tuberculosis for e.g. is a global disease caused by bacterial infection, found in almost every country in the world. It is the leading (infectious) cause of death worldwide, killing someone approximately every 21 seconds — for reference, about 1.5 million deaths in 2018 alone; compared to the approximately 450,000 deaths due to the Covid-19 virus in the last 6 months. Consuming antibiotics at a higher rate is not a sustainable solution as the research community has observed an increase in the evolution of drug resistant strains of bacteria, that has been linked to excessive use of such anti-bacterial drugs.

In the US alone, in 2012, animals consumed more than twice as many medically important antibiotics as humans. Such a heavy dependency and use of anti-bacterial drugs often lead to an increasing number of antibiotic-resistant bacteria like some strains of E.Coli, etc. or antimicrobial resistance (AMR) with multiple or totally resistant pathogens.

Join Gene Quinn, President & CEO of IPWatchdog, Inc. founder and twice named one of the global Top 50 Most Influential People in IP, along with Dirk Caspary, Senior Consultant for PatentSight, for a free webinar discussion.

This webinar is part of the IPWatchdog Weekly Webinar Series.

This Webinar is Sponsored by LexisNexis IP PatentSight